Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

Corbus Pharma's inflammatory disease drug succeeds mid-stage study

12:30pm BST

Oct 19 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum was well tolerated with no severe or serious side effects associated with drug​.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied​.

uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX

12:05pm BST

Oct 19 (Reuters) - uniQure Nv :uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua).

Uniqure announces AMT-061 to enter pivotal study in 2018

12:00pm BST

Oct 19 (Reuters) - Uniqure Nv :Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018.Uniqure NV - ‍plans to initiate pivotal study with enhanced AMT-061 in 2018​.Uniqure nv - ‍acquired patent family that covers FIX-Padua variant and its use in gene therapy for treatment of Coagulopathies, including Hemophilia B​.Uniqure - ‍FDA agreed AMT-061 will be included under existing breakthrough therapy designation and IND for AMT-060​.Uniqure NV - ‍EMA also has agreed that AMT-061 will be included under current prime designation​.

Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist

11:30am BST

Oct 19 (Reuters) - Dynavax Technologies Corp :Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy.Dynavax Technologies - ‍dose escalation study is expected to enroll about 24 patients in 5 cohorts with advanced NSCLC.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary